EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dose Adjustment in Patients with Liver Cirrhosis – Comparison of Two Different Modeling Approaches

Agustos C Ozbey, Fabio Bachmann iD, Urs Duthaler iD, Pieter Annaert iD, Stephen Fowler iD, Kenichi Umehara, Neil Parrott, Stephan Krähenbühl

Clinical Pharmacology & Therapeutics · 2023-06 · 113 (6) · 1346-1358

DOI: 10.1002/cpt.2897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 20.04.2023. Verfasst von Agustos C Ozbey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Liver Cirrhosis, Alkynes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Failure to perform adequate dose adjustment in patients with liver cirrhosis may be associated with increased toxicity. We compared the prediction of area under the curve (AUC) and clearance for the six compounds of the Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, and midazolam) using a well‐known physiology‐based pharmacokinetic approach (physiologically‐based pharmacokinetic [PBPK] approach, Simcyp) and a novel top‐down method based on the systemic clearance in healthy volunteers adjusted for markers of liver and renal dysfunction (“top‐down approach”). With few exceptions, plasma concentration‐time curves were accurately predicted by the PBPK approach. In comparison to the measured AUC and clearance of these drugs in patients with liver cirrhosis and healthy controls, except for efavirenz, the estimates of both approaches were within two standard deviations of the mean for total and free drug concentrations. For both approaches, a correction factor for dose adjustment in patients with liver cirrhosis could be calculated for the drugs administered. AUCs calculated using the adjusted doses were comparable to the AUCs measured in control subjects, with slightly more accurate predictions generated by the PBPK approach. For drugs with a free fraction < 50%, predictions using free drug concentrations were more accurate than with total drug concentrations. In conclusion, both methods provided good qualitative predictions of the changes by liver cirrhosis in the pharmacokinetics of the six compounds investigated. The top‐down approach is easier to implement but the PBPK approach predicted changes in drug exposure more accurately than the top‐down approach and provided reliable estimates for plasma concentrations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisAlkynesHumansBenzoxazinesCyclopropanesModels, Biological

Substanzen

efavirenzAlkynesBenzoxazinesCyclopropanes

Autor:innen und Institutionen

  • Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Department of Drug Delivery and Disposition, KU Leuven, Leuven, Belgium.
  • Division of Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland.
  • Department of Clinical Research, University of Basel, Basel, Switzerland.
  • Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.

ORCID-Profile: Fabio Bachmann, Urs Duthaler, Pieter Annaert, Stephen Fowler

Zitieren

APA

Ozbey, A. C., Bachmann, F., Duthaler, U., Annaert, P., Fowler, S., Umehara, K., Parrott, N., & Krähenbühl, S. (2023). Dose Adjustment in Patients with Liver Cirrhosis – Comparison of Two Different Modeling Approaches. Clinical Pharmacology & Therapeutics, 113(6), 1346-1358. https://doi.org/10.1002/cpt.2897

Vancouver

Ozbey AC, Bachmann F, Duthaler U, Annaert P, Fowler S, Umehara K, et al. Dose Adjustment in Patients with Liver Cirrhosis – Comparison of Two Different Modeling Approaches. Clinical Pharmacology & Therapeutics. 2023;113(6):1346-1358. doi:10.1002/cpt.2897

BibTeX
@article{Ozbey2023,
  author = {Ozbey, Agustos C and Bachmann, Fabio and Duthaler, Urs and Annaert, Pieter and Fowler, Stephen and Umehara, Kenichi and Parrott, Neil and Krähenbühl, Stephan},
  title = {Dose Adjustment in Patients with Liver Cirrhosis – Comparison of Two Different Modeling Approaches},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {113},
  number = {6},
  pages = {1346--1358},
  doi = {10.1002/cpt.2897}
}
Kostenlos starten →